• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
Shop

Psychedelics and VR: Exploring New Horizons in Therapeutics and IP

Jayashree Mitra by Jayashree Mitra
June 29, 2022
in Industry
Reading Time: 3 mins read
A A
Psychedelics and VR: Exploring New Horizons in Therapeutics and IP

 

Scientists have argued for a while that psychedelic experiences and virtual reality share the common ability to alter perception and visual processing. EEG recordings suggest that both may induce comparable cortical activity and elicit similar neurological responses. Now, a new generation of researchers are combining virtual reality and psychedelics to create new therapeutic paradigms that improve patient care, also creating opportunities to file patents that capture the evolving innovation.

Several companies have publicized patent filings describing a combination of virtual reality and psychedelics. For example, in June 2021, Goodness Growth Holdings, Inc., announced that its subsidiary, Resurgent Biosciences (Resurgent), had filed for a US patent to create an expansive suite of virtual reality (VR) applications that could be used during psychedelic-based therapies to enhance and guide patients through the experience and potentially create optimized, longer-lasting therapeutic outcomes. In May 2022, Enosis Therapeutics, an Australian medical technology and research company, announced that it was evaluating the integration of virtual reality into existing psychedelic protocols to develop novel technology.

As the technology matures, the industry should expect to see an uptick in patent filings as companies seek to harness the power of virtual reality to create the next generation of psychedelic therapies.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Another company, Incannex Healthcare Limited announced recently that it has executed a license agreement with Monash University to develop a novel treatment that combined Virtual Reality and psychedelics.

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

What should we expect next as the two worlds merge?

 

 

The world of virtual reality

Virtual reality, in the traditional sense, describes an artificial computer-generated three-dimensional environment that users can interact with using devices such as headsets or their mobile phones. Where headsets or other immersive devices are used, the user is often placed inside an experience that stimulates multiple senses including vision, hearing, and touch. There is often a sense of detachment from the actual environment. A subset of virtual reality is augmented reality, where artificial objects are placed within the user’s surroundings, and the user interacts with that object without losing connection with the actual world. This is more common on the mobile side and does not involve the user replacing the live surroundings with an artificial environment that occupies the senses.

Virtual reality has now become a part of the mainstream with technology behemoths developing their own platforms to tap into the enormous market. While gaming and entertainment remain the largest consumer space for virtual reality, alternate applications in healthcare are gaining increased attention. Improvements in both software and hardware are making it easier for consumers to access virtual reality environments, and innovators in the healthcare space are using the promise of virtual reality to improve patient care and offer new therapeutic options.

One such option is combining virtual reality with psychotropic medication to treat mental health conditions, in novel environments that would have been unimaginable even a decade ago.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Combining psychedelics and VR

Purchase Secure Lasix

This combination of psychedelics and virtual reality offers new opportunities for innovators to obtain patent protection, especially where patents on psychedelics alone may be challenging. Psychedelic compounds are well known in the art and are often derived from nature. Thus, the molecule itself cannot be patented. Innovators are seeking different strategies to protect their investment in psychedelics. For example, the industry has seen patents filed on novel crystalline forms, synthetic pathways, extraction protocols, novel formulations, methods of use, and methods of treatment in various disease conditions. As we see more data emerge from clinical trials with psychedelics, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Combining psychedelics with virtual reality opens opportunities to create valuable new intellectual property that can be monetized by emerging companies to support their research and development. The handful of patents that have been treated thus far may well be the predictor of a new therapeutic landscape that has the potential to transform healthcare in ways that seem unimaginable today.

 

Interested in more on VR? Check out Virtual Reality and Psychedelic Therapy: Interview with Entheo Digital CEO

Tags: virtual reality
Jayashree Mitra

Jayashree Mitra

Jayashree Mitra is an accomplished intellectual property attorney with detailed knowledge of the pharmaceutical, biotech, legal cannabis, psychedelics and emerging technology sectors. She can be reached at jmitra@foxrothschild.com

Next Post
Red Light Holland Signs Deal with Wiz Khalifa to Launch Mushroom Brand

Red Light Holland Signs Deal with Wiz Khalifa to Launch Mushroom Brand

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.